Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Jan

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Flipped Nivolumab/Ipilimumab Dosing Improves Outcomes in Advanced Melanoma

In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Untreated CLL

Researchers Create Immune Cell Atlas of Bone Marrow in Patients With Multiple Myeloma

Small Study Examines Potential of Artificial Saliva in Patients With Head and Neck Cancer

Are Food Preservatives Linked to Increased Cancer Risk